Resources

Overcoming regulatory hurdles to secure the UK’s place in the global engineering biology race

LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in children

Poolbeg announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)

Fundraising, collaboration, IP and leadership in focus as founders and investors shared practical advice for scaling in the UK

Firefinch Software sets out what instrument manufacturers need to know about building software that meets Good Manufacturing Practice (GMP) standards

King’s College London has spun out Korecyte Bio Ltd (Korecyte) and Cell and Gene Therapy Catapult (CGT Catapult) has enabled the spinout.

Collaborative Drug Discovery (CDD) announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.

Coulter Partners successfully led a search for Neumirna Therapeutics and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer.

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

Microbiotica announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament

Poolbeg will present data on POLB 001 at the European Hematology Association Congress (EHA), taking place 11-14 June 2026 in Stockholm, Sweden.

Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

Four of the most significant opportunities currently available to engage with global industry leaders

Brainomix announces an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis (PPF).

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.